title: Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
authors.affiliation: Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
authors.forename: Sudhir
authors.initials: S
authors.lastname: Manda
authors.affiliation: Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
authors.forename: Nancy
authors.initials: N
authors.lastname: Dunbar
authors.affiliation: Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
authors.forename: Cynthia R
authors.initials: CR
authors.lastname: Marx-Wood
authors.affiliation: Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. danilov@ohsu.edu.|Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. danilov@ohsu.edu.
authors.forename: Alexey V
authors.initials: AV
authors.lastname: Danilov
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D010880:Piperidines; D011720:Pyrazoles / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*
chemical_list: D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine
keywords: autoimmune haemolytic anaemia; chronic lymphocytic leukaemia; ibrutinib